# DeGen Medical Moves to Dismiss Carlsmed Patent Suit, Vows to Fight Remaining Claims

- Published: 2026-11-15
- Author: [Attorney News](https://attorneynews.net/author/attorneynews-net.md)
- Topics: [News](https://attorneynews.net/news.md)
- Source: https://attorneynews.net/news/degen-medical-moves-to-dismiss-carlsmed-patent-suit-vows-to-fight-remaining-claims/
- Publication: Attorney News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://attorneynews.net/editorial-policy/

*Filing challenges asserted method claims as patent-ineligible abstract ideas*

Florence, SC, Nov. 15, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.globenewswire.com/Tracker?data=PRjZxVheuCOJMOVtcyp-Nng_DN7tWikUBxV4lfYGJQO4v6grzXg4Ntc4PzmIsgJ86zZYnrIAz1WbZS6Qzlw2HG8iuxvtOZpIcgcHpiSOHos=" rel="nofollow">DeGen Medical, Inc.</a> today filed a motion in the U.S. District Court for the District of South Carolina seeking dismissal of key portions of the patent infringement complaint brought by Carlsmed, Inc. (Case No. 4:26-cv-04064-JD).

Carlsmed filed suit on September 15, 2026, asserting eight patents against DeGen's patient-specific spinal implants and related services. DeGen's motion targets the core of that case. It asks the Court to dismiss the asserted method claims of four patents because they claim abstract information processing, which is not eligible for patent protection under Section 101 of the Patent Act. The motion also seeks dismissal of Carlsmed's willfulness allegations and its demand for enhanced damages. It asks the Court to reject two further infringement theories that the Complaint does not plausibly support.

The patents asserted by Carlsmed are directed to automated, computer-implemented methods. DeGen has developed an opposite approach centered on human collaboration, with surgeons and engineers working together to deliver implants designed for individual patients.

"Every DeGen patient-specific implant starts with a conversation between a surgeon and an engineer," said Craig Black, CEO of <a href="https://www.globenewswire.com/Tracker?data=PRjZxVheuCOJMOVtcyp-NmBg-J4apVQUhp2u0dEIqnN_z7j8JJpZk_1Vp9zJeb842lUgDmOhXlU4YESyRtht4QGpzg84R2SyYBBu2CB9eZA=" rel="nofollow">DeGen Medical</a>. "That partnership is how we build our implants, and it is nothing like the automated methods described in the Carlsmed patents. We will vigorously defend our human-centered approach to patient-specific implants."

DeGen is committed to defending this case through to its conclusion and will continue to serve surgeons and patients without interruption.

DeGen is represented by Turner, Padget, Graham & Laney, P.A. (Florence, S.C.) and MacMillan, Sobanski & Todd, LLC (Toledo, Ohio).

CONTACT: Jessica McCracken
DeGen Medical, Inc.
843-407-0538
jessica@degenmedical.com

  
![](https://ml.globenewswire.com/media/ZDBiZmVhNjEtNjkyMS00MDBjLThhMjUtNGNiNjdhZTUxODA1LTExMTAzMDQtMjAyNi0xMS0xNS1lbg==/tiny/DeGen-Medical-Inc-.png)

## Related

- [Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations](https://attorneynews.net/news/kaplan-fox-is-investigating-claims-on-behalf-of-madrigal-pharmaceuticals-inc-nasdaq-mdgl-i.md)
- [NCLA to SCOTUS: Deny Cert in Case Meant to End Courts’ Duty to ‘Set Aside’ Unlawful Agency Rules](https://attorneynews.net/news/ncla-to-scotus-deny-cert-in-case-meant-to-end-courts-duty-to-set-aside-unlawful-agency-rul.md)
- [BETR INVESTOR DEADLINE ONE WEEK AWAY: Bragar Eagel & Squire, P.C. Urgently Reminds Better Home & Finance Holding Company Investors to Contact the Firm Before November 20th](https://attorneynews.net/news/betr-investor-deadline-one-week-away-bragar-eagel-squire-p-c-urgently-reminds-better-home.md)
- [ENDAVA (NYSE: DAVA) Replaces CEO and CFO, Confirms Financial Statements Are Unreliable, Contracts Lack Economic Substance, Financial Restatements Pending – HBSS](https://attorneynews.net/news/endava-nyse-dava-replaces-ceo-and-cfo-confirms-financial-statements-are-unreliable-contrac.md)
